Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tool aims to boost vaccine uptake in Hard-to-Reach communities

NCT ID NCT05866237

Knowledge-focused Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a patient engagement tool (PET) designed to encourage COVID-19 and flu vaccination among underserved populations in East London, including minority ethnic groups, migrants, and low-income individuals. Over 5,900 adults from six GP practices were randomly assigned to receive the PET or standard care. The tool provided culturally adapted educational messages via text, video, or voice. The main goal was to see if the tool increased vaccination rates and was acceptable to patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Patient Engagement Tool (PET) - a culturally adapted educational messaging system (text, video, or voice)
What this could lead to
If successful, this approach could help increase vaccination rates in underserved communities, reducing health disparities.
What could go wrong
This is a pilot study focused on feasibility, not a large-scale trial. The tool may not work in other regions or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

5,903 people

The number who actually took part.

Started

Nov 2023

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Patient registered at study site (included GP surgery) * Adult (aged 18y+) at time of randomisation * Eligible for COVID-19 and/or Flu vaccination (ie. Not received either a first, second or booster vaccination) AND From an underserved population group, defined 1. non-white ethnicity OR 2. resident in a postcode in the bottom 20% of index of multiple deprivation OR 3. Those receiving little or no income We will determine age, ethnicity, post-code and immunisation status from the patients' EMIS records. Exclusion Criteria: * They are unable or unwilling to consent (including those who do not consent to text messaging; those who opt out from taking part in research studies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Vaccination Refusal COVID-19 prevention target influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19 Influenza Vaccination refusal

Contacts and locations

Locations

  • Church Road Health

    London, E12 6AQ, United Kingdom

  • Glen Road Surgery

    London, United Kingdom

  • St Andrews Health Centre/ St Pauls Way Health Centre

    London, United Kingdom

  • St Stephen's Health Centre

    London, United Kingdom

  • Stratford Village Health Centre

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.